Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1746 • ACR Convergence 2024
Global Recruiting Patterns Are Associated with Placebo Response Rates in Clinical Trials of Rheumatoid Arthritis
Andreas Kerschbaumer¹, Marlene Steiner², Pascale Pruckner¹, Josef Smolen³ and Daniel Aletaha⁴, ¹Medical University of Vienna, Vienna, Wien, Austria, ²Medical University Vienna, Vienna, Wien, Austria, ³Medical University of Vienna, Vienna, Austria, ⁴Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Wien, Austria
Background/Purpose: Therapeutic advances of the recent past have led to significant changes in clinical practice when treating patients with rheumatoid arthritis (RA). Since the advent…
Abstract Number: 1881 • ACR Convergence 2024
Cross-State Comparative Assessment of Burden of Rheumatoid Arthritis in the United States and It’s Trend from 1990-2021: A Benchmarking Analysis for the Global Burden of Disease Study 2022
Rafael Sanchez-Dopazo,¹, Eva Kalra², Shadi Abuhashem³, abobakr Saleh⁴, Khalid Faris⁵, Rutvik Raval⁶, Shamitha Hejmadi⁶, Lovekumar Vala⁷, Riya Dhadhal⁸ and Hardik Desai⁹, ¹Larkin Community Hospital Palm Springs Campus, Hialeah, FL, ²Trident Medical Cente, Charleston, SC, ³Alquds University, Jerusalem, West Bank, Palestine, 9458123, Gaza, Palestinian Territories, ⁴kasr alainy Medical School - Cairo University,Egypt/ 11956, Cairo, Egypt, ⁵Studied in Al-Quds university, Palestine, Gaza, Palestinian Territories, ⁶B.J. Medical College, Ahmedabad, India, ⁷Department of Internal Medicine, Shantabaa Medical College and General Hospital, Amreli, Gujarat, India, 365601, Amreli, Gujarat, India, ⁸SMIMER Hospital & Medical College, Surat, Gujarat, India, ⁹Gujarat Adani Institute of Medical Sciences, Bhuj, India
Background/Purpose: The burden of Rheumatoid Arthritis (RA) in the United States is considerable, both in terms of its prevalence and the economic costs it incurs.…
Abstract Number: 1964 • ACR Convergence 2024
Comparison of Knee Minimum Joint Space Width Measurements Using Deep Learning in Patients with Rheumatoid Arthritis and Osteoarthritis Undergoing Total Knee Arthroplasty
Kellen Mulford¹, Elizabeth Kaji¹, Austin Grove¹, Ronnie Sebro², Cody Wyles¹, John Davis¹ and Cynthia Crowson¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Jacksonville, FL
Background/Purpose: While large joint damage is a hallmark of both Osteoarthritis (OA) and Rheumatoid Arthritis (RA), the mechanisms of degradation are substantially different. Minimum joint…
Abstract Number: 2209 • ACR Convergence 2024
Impact of Common Infections on Medication Interruptions, Quality of Life, and Disease Flares in Patients with Rheumatoid Arthritis
Michael George¹, Kelly Gavigan², Shilpa Venkatachalam³, David Curtis², Laura Stradford⁴, William Benjamin Nowell⁵, Joshua Baker¹, Fenglong Xie⁶ and Jeffrey Curtis⁷, ¹University of Pennsylvania, Philadelphia, PA, ²Global Healthy Living Foundation, Upper Nyack, NY, ³Global Healthy Living Foundation, New York, NY, ⁴Global Healthy Living Foundation, Nyack, NY, ⁵Regeneron, New York, NY, ⁶University of Alabama at Birmingham, Birmingham, AL, ⁷University of Alabama at Birmingham, Hoover, AL
Background/Purpose: Serious infections are a major cause of morbidity and mortality in patients with RA, but less is known about more common, non-serious infections. We…
Abstract Number: 2227 • ACR Convergence 2024
Worrisome Mortality Trends over 20 Years Among Patients with Underlying Ischemic Heart Disease and Rheumatoid Arthritis
Yukthi Mudiam¹ and Shreyas Singireddy², ¹Apollo Institute of Medical Sciences and Research, Richmond, TX, ²Department of Cardiology, University of Illinois College of Medicine, Peoria, IL
Background/Purpose: Ischemic heart disease (IHD) is one of the leading causes of death in the United States. Rheumatoid arthritis (RA), a chronic inflammatory condition affecting…
Abstract Number: 2243 • ACR Convergence 2024
A Cross-sectional Study of the Association Between Anxiety State and Various Factors in Patients with Rheumatoid Arthritis
Yusuke Miwa¹, Yuko Miwa² and Michio Hosaka³, ¹Division of Rheumatology, Department of Medicine, School of Medicine, Showa University, Tokyo, Tokyo, Japan, ²Department of Nursing, Showa University School of Nursing and Rehabilitation Sciences, Setagaya-ku, Tokyo, Japan, ³Department of psychosomatic medicine, Katsuyama Clinic, Kawaguchiko, Yamanashi, Japan
Background/Purpose: Although the complication of anxiety in rheumatoid arthritis (RA) patients is reported to be 1.2 times higher than in healthy controls and weakly correlated…
Abstract Number: 2263 • ACR Convergence 2024
The Potential Use of Circulating Extracellular Vesicles for Improved Diagnosis and Therapy in Rheumatic Inflammatory/autoimmune Diseases: Proof of Concept Studies
Gilad Halpert¹, Ori Moskovitch², Linoy Israel², Eri Govrin², Boris Gilburd², Ori Segal², Adi Anaki³, Tal Caller², Daniel Yechiali², Shlomo Segev², Omer Gendelman⁴, Abdulla Watad⁵, Ruty Mehrian-Shai², Rachella Popovtzer³ and Howard Amital⁶, ¹CAHIM SHEBA MEDICAL CENTER, Tel Hashomer, Israel, ²Sheba Medical Center, Ramat-Gan, Israel, ³Bar Ilan University, Ramat-Gan, Israel, ⁴Sheba Medical Center, Ramat Gan, Israel, ⁵Tel Hashomer Medical Center, Ramat Gan, Israel, ⁶Sheba Medical Center, Tel-Hashomer, Israel, Ramat Gan, Israel
Background/Purpose: Many patients with rheumatic conditions do not completely respond or are refractory to biological therapy. Therefore, there are unmet medical needs in the treatment…
Abstract Number: 2281 • ACR Convergence 2024
Assessment of Comparative Efficacy Between Candidate Biosimilar AVT05 and Reference Golimumab
Monica Luque¹, Kristina Zhelyazkova¹, Laxmikant Vashishta², Masna Rai³, Abid Sattar⁴, Richard Bucknall⁴, Steffen Leutz³ and FAUSTO BERTI¹, ¹Alvotech, Zürich, Switzerland, ²Alvotech, Bangalore, India, ³Alvotech, Jülich, Germany, ⁴Alvotech, London, United Kingdom
Background/Purpose: Golimumab is a safe and effective treatment for RA. Biosimilars to the reference product (RP) may make treatment more accessible. We assessed comparable efficacy…
Abstract Number: 2553 • ACR Convergence 2024
Predictors of Biologic and Targeted Synthetic DMARD Initiation for Rheumatoid Arthritis Across Underserved Patient Groups: Insights from a National Cohort Study
Mark Russell¹, Mark Gibson², Benjamin Zuckerman¹, Kanta Kumar³, Shirish Dubey⁴, Maryam Adas², Edward Alveyn², Samir Patel¹, Zijing Yang¹, Katie Bechman², Elizabeth Price⁵, Sarah Gallagher⁶, Andrew Cope², Sam Norton¹ and James Galloway⁷, ¹King's College London, London, England, United Kingdom, ²King's College London, London, United Kingdom, ³University of Birmingham, Birmingham, United Kingdom, ⁴Oxford University Hospitals NHS FT, Oxford, United Kingdom, ⁵Great Western Hospital NHS Foundation Trust, Swindon, England, United Kingdom, ⁶British Society for Rheumatology, London, United Kingdom, ⁷Centre for Rheumatic Diseases, King's College London, London, United Kingdom
Background/Purpose: Quantifying healthcare inequality is essential to addressing the imbalance in outcomes attributable to age, gender, ethnicity and multimorbidity. In this study, we analysed differences…
Abstract Number: 2673 • ACR Convergence 2024
Changes in Mortality Risk After Stopping Glucocorticosteroids – a Population-based Study in Rheumatoid Arthritis
Diane Lacaille¹, Coraline Danieli², Kasra Moolooghy¹ and Michal Abrahamowicz³, ¹Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ²Research Institute of McGill University Health Center (RI-MUHC), Montreal, QC, Canada, ³McGill University, Verdun, Canada
Background/Purpose: Glucocorticosteroid (GC) use is associated with increased mortality risk, especially from cardiovascular diseases (CVD) and infections, with dose and duration of use influencing risk.…
Abstract Number: 0045 • ACR Convergence 2024
Proteomic Analysis of the Rheumatoid Arthritis Citrullinome Reveals an Enrichment of Citrullinated Complement Proteins
Khushali Trivedi¹, Clarissa Klenke², Jun Kim¹, Jeba Atkia Maisha², Alina Sememenko¹, XIAOBO MENG², Mario Navarrete¹, Hani El-Gabalawy² and Liam O'Neil², ¹University of Manitoba, Winnipeg, Canada, ²University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Citrullination is a key physiological process that drives autoantibody formation in Rheumatoid Arthritis (RA). This irreversible post-translational modification of the amino acid arginine is…
Abstract Number: 0063 • ACR Convergence 2024
Splicing into Action:Investigating the Role of Alternative Splicing in Rheumatoid Arthritis Neutrophils
Rayan Najjar¹, Noga Rogel² and Tomas Mustelin³, ¹University of Washington, Seattle, ²University of Washinton, Seattle, ³University of Washington, Seattle, WA
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by a variable response to therapies, reflecting its complex and incompletely understood pathogenesis. Emerging research suggests…
Abstract Number: 0152 • ACR Convergence 2024
Hydroxychloroquine and Chloroquine Retinopathy in Hispanic Patients with Rheumatic Diseases
Janett Riega Torres¹, Karina Palomo-Arnaud², Gabriel Figueroa-Parra¹, Fernando Morales Wong¹, Jesús Hernán González Cortés¹, Jesus Mohamed Hamsho¹, Jorge Esquivel-Valerio¹, Dionicio Galarza-Delgado³ and Karim Mohamed Noriega¹, ¹Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ²Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, San Nicolás de los Garza, Mexico, ³UANL Hospital Universitario, Monterrey, Nuevo León, Mexico
Background/Purpose: Antimalarial drugs like hydroxychloroquine (HCQ) and chloroquine (CQ) are among the most frequently prescribed medications in Rheumatology. Retinal toxicity is an unwanted side effect…
Abstract Number: 0232 • ACR Convergence 2024
Subjective and Objective Measures of Disease Activity in Difficult-to-Treat Rheumatoid Arthritis Patients at Baseline and Follow-up After an Advanced Therapy: An Ultrasound Study
Seyyid Bilal Acikgoz¹, Ricardo Sabido-Sauri², Ozun Bayindir Tsechelidis³, Ummugulsum Gazel², Sylvia Sangwa⁴, Elliot Hepworth² and Sibel Aydin⁵, ¹University of Ottawa, Rheumatology, Ottawa, ON, Canada, ²University of Ottawa, Ottawa, ON, Canada, ³Ottawa University, Ottawa, ON, Canada, ⁴The Ottawa Hospital Research Institute, Ottawa, Canada, ⁵University of Ottawa - Ottawa, Ottawa, ON, Canada
Background/Purpose: In the era of several advanced therapies and an increasing number of patients with rheumatoid arthritis (RA) who have been failed by multiple therapies,…
Abstract Number: 0427 • ACR Convergence 2024
Association of Menopause and Systemic Rheumatic Disease Severity in Peri-Menopausal and Menopausal Women with Systemic Rheumatic Disease
Lucy Masto¹, Amaya Smole², Ranqing Lan¹, Michael Parides¹, Caroline Siegel¹, Sarah Lieber¹, Jonah Levine¹, Bessie Stamm¹, Lisa Mandl¹, Michael Lockshin³, Lisa Sammaritano⁴ and Medha Barbhaiya¹, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Amherst, MA, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁴Hospital for Special Surgery, Scarsdale, NY
Background/Purpose: The relationship between menopause and systemic rheumatic disease (SRD) severity in women with SRDs is poorly understood. Few studies evaluating this association suggest worsening…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.